Denali Therapeutics Inc (DNLI)
17.14
+0.33
(+1.96%)
USD |
NASDAQ |
May 03, 16:00
17.14
0.00 (0.00%)
After-Hours: 20:00
Denali Therapeutics Cash from Investing (Quarterly): 73.05M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 73.05M |
| September 30, 2023 | 100.91M |
| June 30, 2023 | 168.07M |
| March 31, 2023 | -92.72M |
| December 31, 2022 | -127.56M |
| September 30, 2022 | 15.42M |
| June 30, 2022 | 88.63M |
| March 31, 2022 | -117.88M |
| December 31, 2021 | -40.75M |
| September 30, 2021 | -53.01M |
| June 30, 2021 | 97.54M |
| March 31, 2021 | -25.40M |
| December 31, 2020 | -367.34M |
| September 30, 2020 | -212.12M |
| Date | Value |
|---|---|
| June 30, 2020 | -30.41M |
| March 31, 2020 | -13.33M |
| December 31, 2019 | 42.38M |
| September 30, 2019 | 49.49M |
| June 30, 2019 | 63.88M |
| March 31, 2019 | -8.047M |
| December 31, 2018 | -61.40M |
| September 30, 2018 | 44.73M |
| June 30, 2018 | 30.53M |
| March 31, 2018 | -301.27M |
| December 31, 2017 | -95.15M |
| September 30, 2017 | 16.53M |
| June 30, 2017 | 22.07M |
| March 31, 2017 | 15.38M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-367.34M
Minimum
Dec 2020
168.07M
Maximum
Jun 2023
-20.06M
Average
-13.33M
Median
Mar 2020
Cash from Investing (Quarterly) Benchmarks
| Halozyme Therapeutics Inc | -8.291M |
| AIM ImmunoTech Inc | -0.214M |
| Perspective Therapeutics Inc | -0.089M |
| Protalix BioTherapeutics Inc | -0.342M |
| Armata Pharmaceuticals Inc | -2.39M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -98.66M |
| Cash from Financing (Quarterly) | 4.705M |
| Free Cash Flow | -370.93M |
| Free Cash Flow Per Share (Quarterly) | -0.7298 |
| Free Cash Flow Yield | -15.64% |